AbbVie expects continued Humira strength

AbbVie Inc. (NYSE:ABBV) gained $5.45 (10%) to $59.55 on Friday after reporting 3Q15 earnings and forecasting revenues of $37 billion by 2020, driven largely by sales of Humira adalimumab.

Humira sales were $3.6 billion in 3Q15, up 12% from $3.3 billion in 3Q14. The company expects sales of the drug to exceed $18 billion in 2020. ...